Firalis
Firalis is a France-based biotechnology company offering proprietary multi-omics biomarker panels (cardiac, neurodegenerative, autoimmune) and CRO services in proteomics, genomics, and transcriptomics to pharmaceutical, biotechnology, and academic clients.
- Company typePrivate
- Founded2008
- HeadquartersHuningue, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Firalis does
Firalis S.A. is a private biotechnology company founded in 2008 in Huningue, France, at the triple border of France-Germany-Switzerland within the BioValley cluster adjacent to Basel. The company specializes in biomarker discovery, development, and regulatory qualification for precision medicine, operating a multi-omics platform that combines proteomics (Olink Proseek panels, Quanterix Simoa), genomics (Illumina NextSeq 500 NGS), and transcriptomics. Its proprietary product portfolio includes the FIMICS cardiac long non-coding RNA (lncRNA) panel quantifying 3,233 cardiac-enriched targets, the BIOPRED mRNA panel for inflammatory-autoimmune disorders, NEUROLINCS for neurodegenerative disease, and the MEMORYLINC blood-based Alzheimer's test; the affiliate Amoneta Diagnostics received CE-IVDR marking for the APO-Easy Genotyping Kit in 2024.
Firalis operates a hybrid business model spanning contract research organization (CRO) services, Research-Use-Only (RUO) and In-Vitro Diagnostic (IVD) kit commercialization, EU-funded research grants, and third-party CE-IVDR certification services delivered through a new bioproduction facility. The company sells directly to pharmaceutical and biotechnology clients, including named partners such as Sanofi and Servier in the PACIFIC heart failure consortium, Astellas, QuantaMatrix, and Seoul National University Hospital, with distribution partnerships in South Korea and Japan. Pricing is quotation-based, and the company maintains certifications across ISO 13485, ISO 17025, ISO 9001, ISO 14001, and NF S 96-900.
Revenue mechanics rely on a combination of professional services fees, one-time kit sales, non-dilutive grant funding (cumulative >€20M from Horizon 2020, IMI, FP7, Eurostars, Bpifrance, and ANR), and approximately €3M in venture capital and crowdfunding. The company employs 60 people (25% PhDs) and is investing in a 4,000 sqm bioproduction facility in Huningue (€7.2M total project; €1.284M from France 2030) expected operational by 2026, with planned headcount growth of more than 100 jobs by 2029.
Firalis firmographics
Firmographics- Name
- Firalis
- Legal name
- Firalis S.A.
- Website
- https://firalis.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Firalis is a France-based biotechnology company offering proprietary multi-omics biomarker panels (cardiac, neurodegenerative, autoimmune) and CRO services in proteomics, genomics, and transcriptomics to pharmaceutical, biotechnology, and academic clients.
- Ownership category
- akta.pro rank
Firalis industry classification
Industry- Product category
- Biomarker Diagnostics & Contract Research Services
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)
- akta.pro secondary industries
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Proteomics & Biomarker Analytical Testing (HLAGADAG)
Keywords
Where Firalis is headquartered
LocationHeadquarters
- HQ city
- Huningue
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
Firalis business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- CRO Biomarker Services: Provides comprehensive biomarker services from discovery to clinical qualification including proteomics, genomics, transcriptomics, assay development, and biobanking services to pharmaceutical and biotech companies.
- RUO and IVD Kit Sales: Commercialization of Research-Use-Only and In-Vitro Diagnostic kits including FIMICS, BIOPRED, NEUROLINCS, MEMORYLINC panels, and ELISA kits for cardiovascular, neurodegenerative, and inflammatory diseases.
- Research Grants: European Commission and government funding from programs including IMI, FP7, Eurostars, Horizon 2020, France 2030 for R&D projects.
- CE-IVDR Certification Services: Third-party diagnostic candidates offered CE-IVDR certification services at new bioproduction facility.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom quotation-based pricing |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Firalis product offering
Product offeringCore offering
Firalis provides biomarker discovery, development, and regulatory qualification services to pharmaceutical, biotech, and academic clients through its multi-omics CRO platform (proteomics, genomics, transcriptomics, assay development, biobanking). The company also manufactures and commercializes proprietary RUO and IVD biomarker kits — FIMICS (cardiac lncRNAs), BIOPRED (inflammatory mRNAs), NEUROLINCS and MEMORYLINC (neurodegenerative lncRNAs), ELISA kits, and IVD products such as EasyCOV (COVID-19 saliva test) and APO-Easy (Alzheimer's APOE genotyping). All production takes place in ISO 13485/ISO 17025/NF S 96-900 certified facilities in Huningue, France.
Product overview
Firalis is a biotechnology company offering a comprehensive biomarker-based diagnostic portfolio combined with CRO services. The product suite includes RUO (Research-Use-Only) diagnostic kits (FIMICS for cardiac lncRNAs, MEMORYLINC and NEUROLINCS for neurodegenerative diseases, BIOPRED for inflammatory disorders, ELISA Kits) and IVD products (EasyCOV COVID-19 test, APO-Easy Genotyping Kit). The company provides biomarker services including proteomics (Olink, Quanterix platforms), genomics (NGS, Illumina NextSeq 500), and assay development. All products and services are supported by GMP-compliant facilities certified ISO 13485, ISO 17025, ISO 9001, and biobanking under NF S 96-900 standards.
Differentiator
Problem solved
Functional benefit
Brands
- Firalis Molecular Precision: Subsidiary brand for large-scale protein identification and genomics services including Olink, Quanterix, and Next Generation Sequencing
- Lodiag
- FIMICS
- NEUROLINCS
- MEMORYLINC
- BIOPRED
Products and services
- FIMICS Long non-coding RNA (lncRNA) research-use-only panel quantifying 3,233 cardiac-enriched lncRNAs in peripheral blood samples for characterization of patients with diverse cardiac disorders and toxicities, leveraging NGS with ~55,000 capture probes.
- MEMORYLINC Blood-based non-coding RNA RUO panel for early diagnosis of Alzheimer's disease and other neurodegenerative conditions.
- NEUROLINCS Targeted sequencing RUO panel quantifying ~7,500 brain-enriched lncRNAs from blood samples for research on cognitive impairment, Alzheimer's, and neurodegenerative diseases.
- BIOPRED mRNA targeted gene sequencing RUO panel quantifying over 2,100 mRNAs in whole blood (PAXgene RNA tubes) for inflammatory-autoimmune disorder research, using extraction-free HTG EdgeSeq chemistry with reproducibility mean R > 0.99.
- ELISA Kits Colorimetric sandwich ELISA kits developed and validated by Firalis for quantitative biomarker measurement in blood-derived matrix samples.
- EasyCOV COVID-19 Saliva Test CE-marked, non-invasive saliva-based IVD test using colorimetric detection for SARS-CoV-2, with HAS validation and reimbursement recommendation in France.
- APO-Easy Genotyping Kit CE-IVDR certified qualitative IVD real-time PCR test for detection of APOE genotypes (rs429358 and rs7412) supporting Alzheimer's disease diagnostics and risk stratification.
- Proteomics CRO Services (Olink / Quanterix Simoa) CRO biomarker services using Olink Explore, Target, and Flex Proximity Extension Assay platforms (92+ biomarkers per panel from <50 µl samples) plus Quanterix Simoa ultra-low protein quantification.
- Genomics CRO Services (Illumina NextSeq 500 NGS) CRO genomics services delivering Illumina Propel-certified NextSeq 500 NGS including RNA-Seq, miRNA profiling, exome sequencing, methylation analysis, single-cell sequencing, spatial transcriptomics, and custom RT-qPCR.
- Assay Development & Production Services CRO assay development, validation, and ISO 13485/ISO 17025-compliant production of biological materials and CE-marked IVD kits for pharma and diagnostic partners.
- Clinical Samples / Biobank Services Clinical biological samples and biobanking services operated under NF S 96-900 certification, with Firalis' biobank moving toward registration as a BBMRI-ERIC node.
- Recombinant Proteins / Calibrants Catalog of recombinant proteins and calibrants for research and diagnostic assay development.
- Monoclonal Antibodies Catalog monoclonal antibodies for biomarker detection and diagnostic assay development.
Quantifiable outcome
- 100+ clinical and pre-clinical biomarker research projects completed
- +5 more outcomes
Companies that use Firalis
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Firalis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration7 records
AI capability8 records
Feature8 records
Firalis partnerships and signals
Strategic signalPartnerships
23 partnerships are on record, tiered minor and core.
- ONCOSCREEN Consortium (~40 partners)minorEU Horizon Europe project for colorectal cancer screening. €14 million project integrating AI, genomic biomarkers, and citizen feedback for early CRC detection.
- VOLABIOS Consortium (18 partners)coreHorizon Europe project for schizophrenia diagnosis using multi-omics volatolomics biomarkers. Firalis leads VOC biomarker validation with genomics, proteomics, transcriptomics expertise.
- Rostock Medicine UniversityminorCombiDiag doctoral network coordinator hosting summer school at Firalis for Alzheimer's biomarker research training.
- ADAPT Centre at Trinity College DublincorePARADISE project coordinator for personalized prediction tool for autoimmune disease recurrence. Project kick-off April 2023 for three-year duration.
- Luxembourg Institute of Health (LIH)coreCOVIRNA project coordinator for COVID-19 cardiovascular complications diagnostic test development. FIMICS panel based prognostic device development with 3.88 M€ EC funding.
- OlinkcoreOlink certified service provider offering Proseek panels for COVID-19 research at exceptional prices. Each panel measures 92 biomarkers simultaneously.
- SkillCellcoreEasyCOV saliva test production partnership for COVID-19 diagnostic. Firalis produces tests at industrial scale. HAS validated for use and reimbursement.
- Sys2Diag/CNRScoreEasyCOV consortium partner for COVID-19 saliva test development with validation by French health authorities.
- VOGOminorEasyCOV consortium partner providing technology startup expertise for COVID-19 diagnostic test development.
- AstellasminorJapanese pharmaceutical company collaboration beginning for biomarker research services.
- SanoficorePACIFIC consortium partner (5-year project) for redefining heart failure with preserved ejection fraction (HFpEF). Sanofi leads consortium with Firalis providing biomarker expertise.
- ServiercorePACIFIC consortium partner contributing expertise in data management and biostatistics for heart failure research alongside Sanofi.
- Assistance Publique - Hôpitaux de Paris (AP-HP)corePACIFIC consortium coordinator for clinical study with five cardiology hospitals and clinical investigation centers recruiting patients.
- InsermcorePACIFIC consortium partner providing expertise in biomedical ultrasound and cardiovascular imaging analysis through research units.
- BioserenityminorPACIFIC consortium partner developing connected textiles for remote patient monitoring in heart failure management.
- CASISminorPACIFIC consortium partner developing AI image analysis software for cardiac imaging.
- FealinxminorPACIFIC consortium partner developing AI algorithms for heart failure data analysis.
- Celemics Inc.coreCo-development and commercialization agreement for FIMICS lncRNA panel using Celemics targeted enrichment technology for Next-Generation Sequencing. Joint product development.
- HTG Molecular DiagnosticscorePlatform partner for Biopred panel development using HTG EdgeSeq system for extraction-free targeted mRNA profiling.
- IlluminacorePropel certified partner for NextSeq 500 sequencing platform ensuring high quality sequencing data and best practice compliance.
- CHU de ToulousecoreHeartLinc project European clinical partner for AMI patient profiling (150 patients in France).
- QuantaMatrixcoreCo-development and distribution agreement for IVD products in South Korea. Partner in HeartLinc project developing heart failure diagnostic test on Fi-MAP platform.
- Seoul National University Hospital (SNUH)coreHeartLinc project partner for heart failure diagnostic test validation in Asian AMI patients (150 patients).
Scale indicators11 records
Recent moves7 records
Expansion highlights7 records
Firalis competitors and assessment
Company assessmentBroad incumbents
- Qiagen: Qiagen is a global molecular sample-prep and diagnostic company offering companion diagnostics, IVD kits, and biomarker services. Broader portfolio but directly competes with Firalis on IVD assay development and pharmaceutical biomarker services for pharma partners.
- Myriad Genetics: Myriad is an established molecular diagnostics company commercializing blood-based and tissue-based companion and IVD tests (e.g., myChoice HRD, Vectra). Firalis's IVD strategy for cardiovascular and neurodegenerative biomarkers follows a similar companion-diagnostic commercialization model at smaller scale.
- Bio-Rad Laboratories: Bio-Rad provides life science research and clinical diagnostics products including ddPCR, digital ELISA, and biomarker kits. Overlaps with Firalis's ELISA kit offerings and proteomics CRO services for pharma and academic customers.
Direct peers
- NanoString Technologies: NanoString offers spatial transcriptomics and targeted gene expression profiling (GeoMx, nCounter) serving the same pharma and translational research customer base as Firalis's genomics services, including direct overlap with Firalis's spatial transcriptomics service line.
- Quanterix: Quanterix provides the Simoa ultra-sensitive protein detection platform used by Firalis as a certified service provider. Comparable biomarker detection technology for neurology and inflammation indications and overlapping pharma/biotech customer base in blood-based biomarker discovery.
- Eurofins Genomics: Eurofins Genomics is a global genomic services and biomarker CRO offering NGS, qPCR, genotyping, and biomarker assay services to pharma and academic customers. Directly comparable to Firalis's genomics/transcriptomics CRO offering and competing for the same European pharma R&D budget.
- HTG Molecular Diagnostics: HTG Molecular Diagnostics develops the EdgeSeq extraction-free targeted mRNA profiling platform that Firalis uses for the BIOPRED panel. Both serve pharma biomarker discovery with targeted RNA panels, making HTG a partner-and-competitor with direct product overlap in inflammatory-autoimmune profiling.
Emerging players
- Biodesix: Biodesix is a blood-based diagnostics company developing proteomic and multi-omic tests for oncology and lung disease. Comparable as an emerging blood-based biomarker diagnostic company pursuing similar indications and reimbursement pathways as Firalis's MEMORYLINC and FIMICS.
- QuantaMatrix: QuantaMatrix developed the Fi-MAP multiplexed gene-expression IVD platform used in the HeartLinc project with Firalis and Seoul National University Hospital. Overlapping focus on molecular diagnostics for infectious disease and cardiology with similar Asian market channel strategy.
- Celemics: Celemics is a Seoul-based targeted NGS enrichment and sequencing company that co-developed the FIMICS panel with Firalis. Comparable as a smaller emerging player in the targeted sequencing/biomarker panel market and a partner-competitor for next-gen sequencing diagnostics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Firalis social profiles
Digital presenceFiralis compliance and trust
Trust signalCompliance8 records
Firalis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Firalis leadership team
Management profileNumber of profiles
Profiles4 records
Firalis subsidiaries and ownership
Company hierarchySubsidiaries1 record
Firalis funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Firalis M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Firalis
What does Firalis do?
Firalis provides biomarker discovery, development, and regulatory qualification services to pharmaceutical, biotech, and academic clients through its multi-omics CRO platform (proteomics, genomics, transcriptomics, assay development, biobanking). The company also manufactures and commercializes proprietary RUO and IVD biomarker kits — FIMICS (cardiac lncRNAs), BIOPRED (inflammatory mRNAs), NEUROLINCS and MEMORYLINC (neurodegenerative lncRNAs), ELISA kits, and IVD products such as EasyCOV (COVID-19 saliva test) and APO-Easy (Alzheimer's APOE genotyping). All production takes place in ISO 13485/ISO 17025/NF S 96-900 certified facilities in Huningue, France.
Is Firalis a public or private company?
Firalis is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Firalis founded?
Firalis was founded in 2008. It employs 11 to 50 people.
Where is Firalis based?
Firalis is headquartered in Huningue, France, in the Europe region.
How does Firalis make money?
Four revenue lines are on record. CRO Biomarker Services are the primary driver. The others are RUO and IVD Kit Sales, research Grants and CE-IVDR Certification Services.
Who are Firalis's main competitors?
Broad incumbents on record are Qiagen, Myriad Genetics and Bio-Rad Laboratories. Direct peers are NanoString Technologies, Quanterix, Eurofins Genomics and HTG Molecular Diagnostics. Emerging players are Biodesix, QuantaMatrix and Celemics.
Does Firalis have an API?
No public API is recorded for Firalis.
What industry is Firalis in?
Firalis's product category is Biomarker Diagnostics & Contract Research Services. Its primary akta.pro industry code is HLAAAMAJ, Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 325413 and its SIC code is 2835.